Leech Therapy for Postherpetic Neuralgia
Launched by UNIVERSITÄT DUISBURG-ESSEN · Dec 5, 2012
Trial Information
Current as of May 22, 2025
Terminated
Keywords
ClinConnect Summary
see above
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 to 85 years of age
- • \>6 months thoracal postherpetic neuralgia
- • informed consent
- Exclusion Criteria:
- • if leech therapy is contraindicated
- • physical and mental disability to participate in the study examinations
About Universität Duisburg Essen
The Universität Duisburg-Essen is a prominent academic institution in Germany, renowned for its commitment to research and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, the university leverages its interdisciplinary expertise and state-of-the-art facilities to advance clinical research initiatives. With a focus on improving patient outcomes, the university actively collaborates with healthcare professionals, industry partners, and regulatory bodies to conduct rigorous clinical trials that adhere to the highest ethical and scientific standards. Through its dedication to enhancing clinical knowledge and fostering new therapeutic approaches, Universität Duisburg-Essen plays a pivotal role in the evolution of modern healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Essen, , Germany
Patients applied
Trial Officials
Romy Lauche, PhD
Principal Investigator
Research fellow
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials